| Trial | control | p<0.05 | harm | NS |
|---|
| Zwolle, 1994 | primary ballon angioplasty vs streptokinase | | MACE 0.21 [0.08; 0.55] reinfarction 0.13 [0.03; 0.56] in-hospital mortality 0.27 [0.08; 0.94] | major bleeding 0.87 [0.35; 2.20] stroke 0.33 [0.03; 3.11] |
| Ribeiro, 1993 | primary ballon angioplasty vs streptokinase | | | |
| Grinfeld, 1996 | primary ballon angioplasty vs streptokinase | | | |
| Zijlstra, 1997 | primary ballon angioplasty vs streptokinase | | | |
| DeWood, 1989 | primary ballon angioplasty vs duteplase | | | |
| PAMI, 1993 | primary ballon angioplasty vs t-PA | | | |
| Gibbons, 1993 | primary ballon angioplasty vs duteplase | | | |
| Ribichini, 1996 | primary ballon angioplasty vs accelerated t-PA | | | |
| Garcia, 1997 | primary ballon angioplasty vs accelerated t-PA | | | |
| GUSTO 2B, 1997 | primary ballon angioplasty vs accelerated t-PA | | | |
| DANAMI-2, 1997 | primary ballon angioplasty vs accelerated t-PA | | | |
| Zijlstra , 1993 | primary ballon angioplasty vs streptokinase | | | |
| Akhras, 1997 | primary ballon angioplasty vs streptokinase | | | |
| O'Neill, 1986 | primary ballon angioplasty vs intracoronary streptokinase | | | |
| TRIANA, 2009 | primary ballon angioplasty vs tenecteplase | | | MACE 1.46 [0.81; 2.63] stroke 4.03 [0.44; 36.86] reinfarction 1.60 [0.60; 4.26] in-hospital mortality 1.31 [0.67; 2.56] |
| Trial | Treatments | Patients | Method |
|---|
| Zwolle, 1994 | primary PTCA (n=152) vs. streptokinase 1.5 M IU over 1h (n=149) | patients with acute myocardial infarction | open Parallel groups Sample size: 152/149 Primary endpoint: FU duration: discharge |
| Ribeiro, 1993 | primary PTCA (n=50) vs. streptokinase 1.2 M IU over 1h (n=50) | patients with ST segment elevation within 6 h of the onset of chest pain | open Parallel groups Sample size: 50/50 Primary endpoint: FU duration: discharge |
| Grinfeld, 1996 | primary PTCA (n=54) vs. streptokinase 1.5 M IU over 1h (n=58) | | open Parallel groups Sample size: 54/58 Primary endpoint: FU duration: 30 d |
| Zijlstra, 1997 | primary PTCA (n=45) vs. streptokinase 1.5 M IU over 1h (n=50) | atients with acute myocardial infarction | open Parallel groups Sample size: 45/50 Primary endpoint: death, nonfatal stroke or reinfarcti FU duration: 6 months |
| DeWood, 1989 | primary PTCA (n=46) vs. duteplase 0.5 MU/kg for 1 h then 0.7 MU/kg/h for 3h (n=44) | | open Parallel groups Sample size: 46/44 Primary endpoint: FU duration: 30 d |
| PAMI, 1993 | primary PTCA (n=195) vs. t-PA 100mg (or 1.25mg/kg for patients weighting less than 65kg) over 3 h (n=200) | patients who presented within 12 hours of the onset of myocardial infarction | open Parallel groups Sample size: 195/200 Primary endpoint: FU duration: discharge |
| Gibbons, 1993 | primary PTCA (n=47) vs. duteplase 0.6 MU/kg over 5h (n=56) | patients with acute myocardial infarction | open Parallel groups Sample size: 47/56 Primary endpoint: FU duration: discharge |
| Ribichini, 1996 | primary PTCA (n=24) vs. accelerated alteplase 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg) (n=26) | | open Parallel groups Sample size: 24/26 Primary endpoint: FU duration: discharge |
| Garcia, 1997 | primary PTCA (n=95) vs. accelerated t-PA 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg) (n=94) | patients with anterior AMI | open Parallel groups Sample size: 95/94 Primary endpoint: FU duration: 30 d |
| GUSTO 2B, 1997 | primary PTCA (n=573) vs. accelerated t-PA 90 min (15 mg IV bolus followed by an infusion of 0.75 mg/kg over 30min not to exceed 50mg, and then 0.5 mg/kg over the next 60min not to exceed 35mg for a total maximun of 100mg) (n=565) | patients within 12 hours of acute myocardial infarction (with ST-segment elevation on the electrocardiogram) | open factorial design Sample size: 573/565 Primary endpoint: death, nonfatal reinfarction, and nonfatal disabling stroke FU duration: 30 d |
| DANAMI-2, 1997 | angioplasty (n=-9) vs. accelerated treatment with intravenous alteplase (n=-9) | patients who received thrombolytic treatment for a first acute myocardial infarction and with inducible myocardial ischemia (either symptomatic angina pectoris presenting spontaneously > 36 hours after admission or during a predischarge exercise test or ST changes during exercise compatible with ischemia) | open Parallel groups Sample size: -9/-9 Primary endpoint: mortality, reinfarction, and admission with unstable angina FU duration: 2.4y |
| Zijlstra , 1993 | immediate coronary angioplasty (without previous thrombolytic therapy) (n=70) vs. intravenous streptokinase (n=72) | patients with acute myocardial infarction | open Parallel groups Sample size: 70/72 Primary endpoint: FU duration: |
| Akhras, 1997 | primary angioplasty (n=42) vs. streptokinase (n=45) | patient within 12hr from onset of AMI | open Parallel groups Sample size: 42/45 Primary endpoint: none FU duration: |
| O'Neill, 1986 | coronary angioplasty (n=-9) vs. intracoronary streptokinase (n=-9) | patients within 12 hours of their first symptoms of acute myocardial infarction | open Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| TRIANA, 2009 | Tenecteplase + UFH (+/- clopidogrel) (n=132) vs. Primary angioplasty (n=134) | >=75 years old with ST-segment elevation or LBBB AMI <6 hours of evolution without contraindications for thrombolytic therapy | open Parallel groups Sample size: 132/134 Primary endpoint: Death or Reinfarction or Disabling stroke FU duration: 30 days (12 months) |
